Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the ...

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan.

Lawmakers called for more transparency about how hospitals are using 340B revenue, including audits of participating ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, ...

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Sen. Peter Welch (D-Vt.) has introduced a bill that would ban pharmaceutical companies from restricting access to 340B drug pricing program discounts, according to a Sept. 11 press release shared with ...

Changes to registration requirements for the offsite clinics of 340B-eligible hospitals represent the latest clash between providers, regulators and drugmakers amid the program’s exponential growth.

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

In this podcast, Jason Reddish, Principal and Mark Ogunsusi, Associate, at Powers Pyles Sutter & Verville provide an overview of the program and the compliance requirements. They are also two of the ...